Hemptown Organics Corp (“Hemptown” or the “Company”), is pleased to announce the appointment of Janice Knox and Siddhartha “Sid” Senroy to the Hemptown Advisory Board.
Dr. Janice Knox is a board-certified anesthesiologist. Janice continues to be a much sought-after keynote speaker for cannabis therapeutics domestically and internationally. Dr. Knox is a co-founder of The American Cannabinoid Clinics and ADVENT Academy. She firmly believes that cannabinoid care starts with the understanding of the intricate and complex physiology of the Endocannabinoid System (ECS). Knowledge is rapidly changing as more research uncovers the depth of the ECS. Dr. Janice is a board member of the American Academy of Cannabinoid Medicine (AACM) and Co-founder of the Products with Purpose Initiative, an initiative working to create a standard of products based on the pharmacology of cannabis and the physiology of the ECS. The initiative pushes for the philosophy of conscientious capitalism which takes into consideration the environment, social consciousness and responsibility, products created based on science to the efficacy and affordability to the end consumer. Along with her teammates at The American Cannabinoid Clinics, Dr. Knox believes in an integrative approach to delivering medical cannabis care that is rooted in evidence-based Lifestyle and Functional Medicine.
Sid Senroy has an MBA from Pepperdine University and with this foundation, has been able to successfully navigate the business world. Over the last 2 decades, Sid has led several global quality and compliance business units as an executive or as a senior consultant leading to approvals of key blockbuster pharmaceuticals. The cumulative sales of these drugs have exceeded $20 billion annually over the last 10 years. Sid specializes in helping companies pass compliance assessments, develop robust quality systems, and prepare for FDA reviews and inspections. His leadership skills enable him to form cross-functional alliances for improvement and growth. His sensitivity to cultural nuances has helped him to succeed on a global scale. He has worked extensively in Russia, India, Poland, Ukraine, China, Japan, South Africa, and Australia to name a few countries.
“We are excited for what the future holds for Hemptown. We strongly believe with the help of our highly equipped Advisory Board, that we will take the Company to new heights in 2020 and beyond,” said Eric Gripentrog, CEO of Hemptown. “These two exceptional individuals are at the forefront of their respective industries, and we know with their support and expertise that we will enhance our products and services, ultimately increasing Hemptown’s reach globally.”
About Hemptown Organics Corp.
Hemptown is growing some of the finest hemp in the world to meet the global demand for cannabinoid-based products. Farmland spanning three states, product manufacturing capability and a strong leadership team are the pillars for Hemptown’s growth model as the Company pushes into the consumer-packaged goods sectors with top quality white label and branded product lines for the consumer market. Hemptown’s fully operational (FDA-licensed and cGMP certified) nutraceutical manufacturing facility in Oregon gives the company a strong leadership position in a global market that continues to grow exponentially. For more information, visit www.hemptownusa.com.
Hemptown Investor Relations
Disclaimer for Forward-Looking Statements
This news release contains forward-looking statements that involve various risks and uncertainties regarding future events. Such forward-looking statements are based on current expectations of management, involve a number of risks and uncertainties, and are not guarantees of future performance of Hemptown (the company). These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing date of the financing, the attributes of the securities to be offered and sold by the Company, the proposed use of the net proceeds of the Offerings. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include general market conditions, significant business, competitive, political and social risks and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Aurora Cannabis Announces Filing of Preliminary Base Shelf Prospectus and Provides Update on Balance Sheet Strength
- Existing At-The-Market (ATM) program now complete
- New Preliminary Base Shelf Prospectus Has Been Filed
- Current Cash Position is Approximately $272 million
NYSE | TSX: ACB
Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously filed At-The-Market (“ATM”) program. Because of this, the Company has filed a new preliminary short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada except Quebec and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).
Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.
Inaugural runs of the award-winning and new white-label brands will allow the infused beverage expert to move ahead quickly with commercialization plans
Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) (FSE:7BC) (“BevCanna” or the “Company”) is pleased to announce that it has successfully completed the R&D and trial production runs of its exclusively licenced award winning line of Keef Beverages and the white-label beverages the Company is producing for State B Beverages.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.
“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.